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Abstract
Background:  Gingival overgrowth (GO) is a common side effect of the chronic use of
cyclosporine (CsA), an immunosuppressant widely used to prevent rejection in transplant patients.
Recent studies have reported elevated levels of specific cytokines in gingival overgrowth tissue,
particularly TGF-beta, suggesting that this growth factor plays a role in the accumulation of
extracellular matrix materials. The effectiveness of azithromycin, a macrolide antibiotic, in the
regression of this undesirable side effect has also been demonstrated.
Methods: In this study, we created an experimental model for assessing the therapeutic effect of
roxithromycin in GO and the expression of transforming growth factor beta (TGF-beta2) through
immunohistochemistry. We used four groups of rats totaling 32 individuals. GO was induced during
five weeks and drug treatment was given on the 6th week as follows: group 1 received saline; group
2 received CsA and was treated with saline on the 6th week; group 3 received CsA and, on the 6th
week, ampicilin; and group 4 received CsA during 5 weeks and, on the 6th week, was treated with
roxithromycin.
Results:  The results demonstrated that roxithromycin treatment was effective in reducing
cyclosporine-induced GO in rats. Both epithelial and connective tissue showed a decrease in
thickness and a significant reduction in TGF-beta2 expression, with a lower number of fibroblasts,
reduction in fibrotic areas and decrease in inflammatory infiltrate.
Conclusion: The present data suggest that the down-regulation of TGF-beta2 expression may be
an important mechanism of action by which roxithromycin inhibits GO.
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Background
Gingival overgrowth (GO) is a common side effect of cer-
tain drugs, such as phenytoin, calcium channel blockers
and cyclosporin [1,2].
Cyclosporine (CsA) has been widely used to prevent
organ transplant rejection and to treat various immuno-
diseases [2]. It selectively suppresses helper T-cell function
and modulates the network of inflammatory cytokines.
However, CsA is associated with several adverse effects,
such as nephrotoxicity, hepatotoxicity, hirsutism and gin-
gival overgrowth (GO) [1,3,4]. The average prevalence of
dentate transplant patients who develop cyclosporine
induced GO is around 30%, with variation between 10
and 85% [5-9]. When associated with other medication,
such as calcium channel blocker antihypertensives, this
prevalence increases, as does the gravity of the complica-
tion, and, consequently, the risk [10-13].
Fibrosis, one of the most important finding in GO, is the
result of a variety of biochemical signals from many cell
types including inflammatory cells and fibroblasts, which
stimulate fibroblast proliferation and extracellular matrix
production [14]. The transforming growth factor beta
(TGF-beta) is a multifunctional family of cytokines
present in this pathway and there are three mammalian
isoforms of TGF-beta (TGF- beta1, TGF-beta2 and TGF-
beta3), which are structurally similar [15]. Increased TGF-
beta1 levels have been associated in cyclosporin-induced
renal fibrosis [16]. Most of the studies argue in favor of
TGF-beta1 in the CsA-induced gingival overgrowth. How-
ever a few number of studies investigated the expression
of TGF-beta2 in this pathological condition [15,17]. TGF-
beta2 is considered an immunosuppressive cytokine
modulated by cyclosporine that plays a central role during
the formation of fibrosis and inflammatory reaction [18-
20]. Recently, it was demonstrated that roxithromycin has
an inhibitory effect on the production of TGF-βbeta by
human mesangial cells, and may be efficient in the treat-
ment of glomerulosclerosis [21]. Therefore, this mac-
rolide antibiotic with similar characteristics of
azithromycin, is known to have anti-inflammatory,
immunomodulatory and tissue reparative effects besides
its bacteriostatic activity may be a therapeutic alternative
in the treatment of gingival overgrowth. Recently, we pub-
lished a study with interesting results in renal trans-
planted patients in which the gingival overgrowth was
reduced after roxithromycin treatment [22]. In the present
study we investigated the effect of roxithromycin on GO
in rats treated with cyclosporine. Our findings indicate
that roxithromycin reduces GO and down-regulates TGF-
beta2 expression in gingival tissues.
Methods
Thirty-two 6-week-old male Wistar rats (Rattus novergicus
albinun), weighing 100 to 150 g. were randomly selected
and divided equally into four groups of eight animals
each. The control rats (group 1) were daily injected subcu-
taneously with saline. The experimental rats (group 2)
were treated with CsA injected subcutaneously in a daily
dose of 10 mg/kg for six weeks and, at the beginning of the
6th week, they were injected subcutaneously with saline.
Group 3 was similar to group 2, but in the last week it was
treated with 50 mg/kg ampicillin (an antibiotic widely
used in periodontal infections) via gastric feeding. In
group 4, the animals received CsA daily for 6 weeks and in
the last week they were treated with 40 mg/kg roxithromy-
cin by gastric feeding. The rats were weighed weekly and
the dosage was adjusted accordingly. Diet and drinking
water were given ad libitum during the experiment.
Macroscopy analysis
At the end of the experimental period, all the animals
were sacrificed by means of an overdose of anesthesia
(Kensol® - 10 mg/kg and Vetanarcol® - 90 mg/kg). To
investigate gingival alterations over time, stone models
were made from silicone impressions of the maxillary
anterior region. The higher buccal-lingual width and
mesio-distal width of the anterior segment of the maxilla
were measured using a digital caliper.
Histopathology and histomorphometry
All gingival samples obtained were fixed in 10% buffered
formalin (pH 7) for at least 24 hours. After fixation, the
samples were gradually dehydrated in increasing concen-
trations of ethanol (70% to 100%), cleared in xylene,
soaked and embedded in paraffin, according to routine
histological methods.
The paraffin-embedded fragments were cut with an "820"
Spence microtome and 4 μm thick sections were
obtained. All gingival samples were included in paraffin
with the same orientation. The sections analysed always
showed the epithelium, the connective and muscular tis-
sue. The histometry measurements were performed since
the ephitelium until the muscular tissue. The histological
slides were kept in an incubator to dry, and then the sec-
tions were stained with hematoxylin and eosin for histo-
logical analysis. Histomorphometry was performed using
images captured and evaluated by a computerized Axion
Vision (Zeiss, Berlin, Germany) image capture system.
Images were captured from four randomly chosen micro-
scopic fields for each histological slide, using the digital
camera (400× and 100× magnification) of an Axiostar
Plus microscope (Zeiss, Berlin, Germany) and the number
of TGF-betapositive cells were counted.
The images were stored and submitted to a count of
inflammatory cells and of all fibroblast-like cells. Linear
measurements were made to obtain the higher diameter
of epithelial and gingival connective tissue, using digital
marking.BMC Oral Health 2009, 9:33 http://www.biomedcentral.com/1472-6831/9/33
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Immunohistochemistry
Paraffin sections (4 μm of thick) of formalin-fixed tissue
were obtained at varying depths from each tissue block.
The presence of TGF-beta2 protein in the gingival samples
was investigated in paraffin sections by using the avidin-
biotin-peroxidase complex procedure (ABC) with an
additional step for antigen retrieval with a retrieval solu-
tion (Dakopatts, Copenhagen, Denmark). In brief, the
sections were incubated with polyclonal rabbit anti-TGF-
beta2 antibody diluted 1/20 and incubated for one hour
at room temperature (Santa Cruz, Santa Cruz, USA) fol-
lowed by a goat anti-rabbit IgG biotinylated antibody
(Dakopatts, Copenhagen, Denmark). Controls for the
ABC procedure were performed by replacing anti-TGF-
beta2 antibody with normal rabbit serum, or by omitting
the anti-TGF-beta2 antibody. The sections were analyzed
via light microscopy, and photomicrographs were taken
with an Axiostar Zeiss microscope (Zeiss, Germany). The
number of the TGF-beta2 immunoreactive cells by micro-
scopic field (400 × magnification) was counted in connec-
tive tissue.
Statistical analysis
Data were expressed as means and standard deviation.
ANOVA was used for statistical evaluation and the Bonfer-
roni post-hoc test was used after ANOVA. The gingival
mucosa width, the number of inflammatory cells, all
fibroblast-like cells and TGF-beta2 immunoreactive cells
were compared between groups by using the Student's t-
test. The significance level adopted was p < 0.05.
The manuscript has been performed with the approval of
ethics committee in experimental research on animals by
Federal University of Juiz de Fora/Brazil (protocol n° 039/
2005).
Results
All cyclosporine treated rats presented GO that was evi-
dent in all gingival localizations. Graphic 1 shows macro-
scopic measurements of the buccal-lingual width and
mesio-distal width (p < 0.05). The macroscopic analysis
revealed a significant reduction of the buccal-lingual
width and mesio-distal width in the roxithromycin treated
rats (group 4) when compared with group 2 and group 3
(graphic 1) (p < 0.05). The histopathological analysis
revealed that GO was a result of the enlargement of epi-
thelial and connective tissues (figures 1A, 1B, 1C, 1D). A
moderate acanthosis was observed in animals from
groups 2, 3 and 4. No statistical differences were observed
when compared the thickness of the epithelium detected
Macroscopic measurements of buccal-lingual and mesio-distal maxillary regions Figure 1
Macroscopic measurements of buccal-lingual and mesio-distal maxillary regions. Results expressed as mean and 
the level of significance for statistical analyse was p < 0.05. G1 (n = 8 animals) - negative control group - administration of saline 
solution. G2 (n = 8 animals) - positive control group - administration of CsA + saline. G3 (n = 8 animals) - positive control 
group- - administration of CsA + AMP. G4 (n = 8 animals) - treated group - administration of CsA + ROX.BMC Oral Health 2009, 9:33 http://www.biomedcentral.com/1472-6831/9/33
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in gingival samples obtained from the control positive
groups with the treated groups. A severe hyperplasia of
collagen fibres were observed in the gingival samples
obtained from groups 2 and 3. However, the microscopic
study revealed a reduction of collagen fibres in gingival
samples of the treated rats when compared with gingival
samples of the control rats. No fibrotic areas were
observed in gingival samples from group 1 (negative con-
trol group). Extensive fibrosis is a common finding in gin-
gival samples from groups 2 and 3, however a few number
of fibrotic areas were observed in gingival tissue of roxi-
thromycin treated rats (figure 2). Diameter measurements
of the epithelial and connective tissues were obtained (fig-
ure 3). The measurements observed in roxithromycin
treated rats (group 4) were statistically lower than those
observed in the GO positive control groups (group 2 and
Representative microscopic fields Figure 2
Representative microscopic fields. A: Normal connective tissue in group 1 (negative control); B-C: Extensive fibrosis in 
groups 2 and 3 (positive controls); D: Few areas with fibrosis in group 4 (treated group). Original magnificance 400×.BMC Oral Health 2009, 9:33 http://www.biomedcentral.com/1472-6831/9/33
Page 5 of 9
(page number not for citation purposes)
group 3). The histomorphometric analysis also demon-
strated that the animals treated with roxithromycin pre-
sented a lower number of fibroblasts per microscopic field
(figure 4). The identification of fibroblasts, based on mor-
phological criteria, was made by two different researchers.
Finally, a lower number of inflammatory cells was
observed in gingival samples obtained from roxithromy-
cin treated group when compared with group 2 and group
3 (figure 5). Cytoplasmatic staining for TGF-beta2 was
detected in most cell types of the connective tissue. TGF-
beta2 was expressed within connective tissue by inflam-
matory cells, fibroblasts and endothelial cells (figure 6).
Most of the fibroblasts and endothelial cells were TGF-
beta2 positive and showed a variable staining pattern,
usually weakly or darkly positive (figure 6). Immunohis-
tochemical analysis showed a lower number of TGF-beta2
positive cells (figure 7) - recognized morphologically as
fibroblasts, endothelial cells and inflammatory cells in the
connective tissue samples from roxithromycin treated rats
when compared with GO positive controls rats (group 2,
and group 3) (figure 7). No significant differences were
detected when compared to the number of TGF-beta2
positive cells in gingival samples obtained from group 1
and group 4 (figure 7).
Discussion
Cyclosporine (CsA) is a hydrophobic neutral cyclic
polypeptide composed of eleven amino acids and made
from the fungus Tolypocladium inflatuns gams. It specifi-
cally acts in suppressing the immune response mediated
by T cells. It goes through biotransformation in the liver,
resulting in 14 metabolic products, of which 90% is
excreted in feces and 10% eliminated by the kidneys [23].
Gingival overgrowth is one of the side effects caused by
the chronic use of cyclosporine (CsA), which is employed
to prevent rejection of transplanted organs and to treat
several autoimmune diseases, such as diabetes mellitus,
Behcet's disease, psoriasis, multiple sclerosis, erosive
lichen planus, systemic lupus erythematosus, bullous
pemphigoid, rheumatoid arthritis, myasthenia gravis,
uveitis, and various glomerulopathies [3,24,25].
Several studies have demonstrated elevated levels of spe-
cific cytokines in overgrowth gingival tissue, especially
TGF-beta, a multifunctional inflammatory mediator,
which suggests that this growth factor plays a role in the
accumulation of the extracellular matrix [14,25,26],
including collagenous proteins [27,28]. The TGF-beta iso-
forms may be expressed by most cells, including gingival
Measurements of gingival mucosa (epithelium and lamina propria) Figure 3
Measurements of gingival mucosa (epithelium and lamina propria). Results expressed as mean (p < 0.05). G1 (n = 8 
animals) - negative control group - administration of saline solution. G2 (n = 8 animals) - positive control group - administration 
of CsA + saline. G3 (n = 8 animals) - positive control group- - administration of CsA + AMP. G4 (n = 8 animals) - treated group 
- administration of CsA + ROX.BMC Oral Health 2009, 9:33 http://www.biomedcentral.com/1472-6831/9/33
Page 6 of 9
(page number not for citation purposes)
inflammatory cells, endothelial cells and fibroblasts [17].
Elevated gingival TGF-beta1 and TGF-beta2 have been
suggested by immunohistochemical study on phenytoin
and nifedipine-induced GO [29]. and our data indicate
elevated levels of TGF-beta2 expression on cyclosporin-
induced GO.
GO treatment includes removing bacterial plaque, main-
taining adequate oral hygiene, and also includes invasive
procedures, such as gingivectomy. Treatment for this com-
plication, until recently, was only surgical. Nowadays, sev-
eral studies have been conducted to determine the effect
of antibiotic treatment on the regression of gingival over-
growth. In 1995, Wahlstrom, Zamora and Teichmann
coincidentally used azithromycin - a semi synthetic anti-
biotic, derived from the macrolide erythromycin - to treat
respiratory infections in two renal transplant patients who
had cyclosporine induced GO. They observed gingival
reduction after using it. The daily treatment with 500 mg
for five days is simple, cheap, conservative, quickly effec-
tive, and avoids gingival surgery. It acts mostly against
gram-positive and negative bacteria, has quick oral
absorption, does not alter serum levels of cyclosporine or
levels of creatinine. Azithromycin is well tolerated and
associated an efficient oral hygiene program induce a gin-
gival overgrowth reduction [28], but can produce side
effects, such as diarrhea, abdominal pain, nausea and
vomiting [28-33].
Recently, we used roxithromycin in four renal trans-
planted patients and the results suggest that roxithromy-
cin may be an important therapeutic tool used to reduce
Numbers of fibroblasts per microscopic fields Figure 4
Numbers of fibroblasts per microscopic fields. Five microscopic fields with 400× magnification were studied per histo-
logical slides. Results expressed as mean (p < 0.05). G1 (n = 8 animals) - negative control group - administration of saline solu-
tion. G2 (n = 8 animals) - positive control group - administration of CsA + saline. G3 (n = 8 animals) - positive control group- 
- administration of CsA + AMP. G4 (n = 8 animals) - treated group - administration of CsA + ROX.BMC Oral Health 2009, 9:33 http://www.biomedcentral.com/1472-6831/9/33
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Number of inflammatory cells per microscopic fields Figure 5
Number of inflammatory cells per microscopic fields. Five microscopic fields with 400× magnification were studied per 
histological slides. Results expressed as mean ± SD (p < 0.05). G1 (n = 8 animals) - negative control group - administration of 
saline solution. G2 (n = 8 animals) - positive control group - administration of CsA + saline. G3 (n = 8 animals) - positive con-
trol group- - administration of CsA + AMP. G4 (n = 8 animals) - treated group - administration of CsA + ROX
Representative samples indicated elevated expression of TGF-beta2 in cells of connective tissue (groups 2 and 3); C: Light  TGF-beta2 stained cells in group 4 Figure 6
Representative samples indicated elevated expression of TGF-beta2 in cells of connective tissue (groups 2 and 
3); C: Light TGF-beta2 stained cells in group 4. Red arrows - negative staining cells. Blue arrows: positive staining cells. 
Original magnificance 400×.BMC Oral Health 2009, 9:33 http://www.biomedcentral.com/1472-6831/9/33
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cyclosporine-induced GO [22]. Yamabe et al. (2006) sug-
gested that the use of roxithromycin has an inhibitory
effect on the production of TGF-beta by human mesangial
cells, and can be efficient in the treatment of glomerulo-
sclerosis. The mechanisms that roxithromycin inhibited
TGF-beta production are not clear, but in this study the
drug did not inhibit the activation of tyrosine kinase and
MAP kinase by thrombin. Roxithromycin suppressed the
thrombin-induced translocation of NF-kB p65 protein
into the nucleus. It is suggested that the activation of NF-
kB regulates TGF-beta production, thus ROX inhibited
TGF-beta production via the inhibition of NF-kB.
Conclusion
In the present study, the results demonstrated that roxi-
thromycin treatment was effective to reduce cyclosporine-
induced GO in rats. Both epithelial and connective tissues
showed a decrease in thickness in roxithromycin treated
rats in comparison with animals from the control groups.
In addition, the significant reduction in TGF- beta2
expression in roxithromycin treated rats was associated
with a lower number of fibroblasts, with reduction of
fibrotic areas and decrease in inflammatory infiltrate.
Taken together, our data suggest that the down-regulation
of TGF-beta2 expression may be an important mechanism
of action by which roxithromycin inhibits GO.
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